Catalyst Pharmaceuticals Inc (CPRX)
16.49
+0.09
(+0.55%)
USD |
NASDAQ |
May 17, 16:00
16.74
+0.25
(+1.52%)
After-Hours: 20:00
Catalyst Pharmaceuticals Enterprise Value: 1.637B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 1.637B |
| May 16, 2024 | 1.627B |
| May 15, 2024 | 1.657B |
| May 14, 2024 | 1.637B |
| May 13, 2024 | 1.605B |
| May 10, 2024 | 1.572B |
| May 09, 2024 | 1.538B |
| May 08, 2024 | 1.428B |
| May 07, 2024 | 1.478B |
| May 06, 2024 | 1.460B |
| May 03, 2024 | 1.427B |
| May 02, 2024 | 1.462B |
| May 01, 2024 | 1.484B |
| April 30, 2024 | 1.466B |
| April 29, 2024 | 1.487B |
| April 26, 2024 | 1.447B |
| April 25, 2024 | 1.422B |
| April 24, 2024 | 1.474B |
| April 23, 2024 | 1.428B |
| April 22, 2024 | 1.472B |
| April 19, 2024 | 1.475B |
| April 18, 2024 | 1.500B |
| April 17, 2024 | 1.578B |
| April 16, 2024 | 1.524B |
| April 15, 2024 | 1.506B |
| Date | Value |
|---|---|
| April 12, 2024 | 1.486B |
| April 11, 2024 | 1.556B |
| April 10, 2024 | 1.564B |
| April 09, 2024 | 1.553B |
| April 08, 2024 | 1.520B |
| April 05, 2024 | 1.480B |
| April 04, 2024 | 1.474B |
| April 03, 2024 | 1.518B |
| April 02, 2024 | 1.491B |
| April 01, 2024 | 1.547B |
| March 31, 2024 | 1.571B |
| March 28, 2024 | 1.743B |
| March 27, 2024 | 1.780B |
| March 26, 2024 | 1.719B |
| March 25, 2024 | 1.732B |
| March 22, 2024 | 1.716B |
| March 21, 2024 | 1.821B |
| March 20, 2024 | 1.855B |
| March 19, 2024 | 1.794B |
| March 18, 2024 | 1.758B |
| March 15, 2024 | 1.756B |
| March 14, 2024 | 1.771B |
| March 13, 2024 | 1.821B |
| March 12, 2024 | 1.772B |
| March 11, 2024 | 1.760B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
175.38M
Minimum
Mar 16 2020
1.917B
Maximum
Jan 13 2023
755.09M
Average
490.25M
Median
Enterprise Value Benchmarks
| Pfizer Inc | 219.35B |
| Sarepta Therapeutics Inc | 12.27B |
| PTC Therapeutics Inc | 1.938B |
| Corcept Therapeutics Inc | 2.514B |
| Cytokinetics Inc | 6.241B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 23.28M |
| Revenue (Quarterly) | 98.51M |
| Total Expenses (Quarterly) | 71.38M |
| EPS Diluted (Quarterly) | 0.19 |
| Gross Profit Margin (Quarterly) | 87.29% |
| Profit Margin (Quarterly) | 23.63% |
| Earnings Yield | 3.27% |
| Operating Earnings Yield | 4.15% |
| Normalized Earnings Yield | 3.275 |